Patents Assigned to Cellectar, Inc.
  • Patent number: 10004818
    Abstract: Methods and compositions utilizing ether and alkyl phospholipid ether analog compounds for treating cancer and imaging, monitoring, and detecting cancer stem cells in humans.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: June 26, 2018
    Assignee: CELLECTAR, Inc.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Irawati Kandela, Marc Longino, William R. Clarke
  • Patent number: 9339564
    Abstract: Methods and compositions utilizing ether and alkyl phospholipid ether analog compounds for treating cancer and imaging, monitoring, and detecting cancer stem cells in humans.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: May 17, 2016
    Assignee: CELLECTAR, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Irawati Kandela, Marc Longino, William R. Clarke
  • Publication number: 20150093330
    Abstract: The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Applicant: Cellectar, Inc.
    Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
  • Publication number: 20150044142
    Abstract: The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds.
    Type: Application
    Filed: September 23, 2014
    Publication date: February 12, 2015
    Applicant: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino, Irawati Kandela, William R. Clarke
  • Publication number: 20150030538
    Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 29, 2015
    Applicant: Cellectar, Inc.
    Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
  • Patent number: 8877160
    Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: November 4, 2014
    Assignee: Cellectar, Inc.
    Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
  • Patent number: 8877159
    Abstract: The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: November 4, 2014
    Assignee: Cellectar, Inc.
    Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
  • Patent number: 8871181
    Abstract: The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: October 28, 2014
    Assignee: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino, Irawati Kandela, William R. Clarke
  • Publication number: 20140030187
    Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
    Type: Application
    Filed: August 12, 2013
    Publication date: January 30, 2014
    Applicant: Cellectar, Inc.
    Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
  • Publication number: 20140023587
    Abstract: The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.
    Type: Application
    Filed: August 12, 2013
    Publication date: January 23, 2014
    Applicant: Cellectar, Inc.
    Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
  • Publication number: 20130343991
    Abstract: Methods and compositions utilizing ether and alkyl phospholipid ether analog compounds for treating cancer and imaging, monitoring, and detecting cancer stem cells in humans.
    Type: Application
    Filed: May 6, 2013
    Publication date: December 26, 2013
    Applicant: CELLECTAR, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Irawati Kandela, Marc Longino, William R. Clarke
  • Patent number: 8540968
    Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: September 24, 2013
    Assignee: Cellectar, Inc.
    Inventors: Jamey Weichert, Marc Longino, Anatoly Pinchuk
  • Patent number: 8535641
    Abstract: The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: September 17, 2013
    Assignee: Cellectar, Inc.
    Inventors: Jamey Weichert, Marc Longino, Anatoly Pinchuk
  • Publication number: 20120156133
    Abstract: The present invention provides phospholipid ether and alkyl phospholipid compounds and their combinations with other cancer therapy agents. More specifically, the invention relates to the use of phospholipid ether compounds comprising a “cold” isotope of iodine, e.g. 127I, or H, for treating cancer and combinations of phospholipid compounds comprising radioactive (i.e., “hot”) and non-radioactive (i.e., “cold”) isotopes of iodine.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 21, 2012
    Applicant: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Marc Longino, Jamey P. Weichert, William R. Clarke, Abram M. Vaccaro, Irawati Kandela
  • Publication number: 20120128596
    Abstract: The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds.
    Type: Application
    Filed: May 11, 2010
    Publication date: May 24, 2012
    Applicant: CELLECTAR, INC.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino, Irawati Kandela, William R. Clarke
  • Patent number: 8022235
    Abstract: The present invention discloses boronic acids and esters of phospholipid ether analogs and methods for their synthesis and use. The boronic acids and esters of phospholipid ether analogs described herein can be used in treating cancer and in particular can be used in conjunction with radiation therapy, such as external beam radiation therapy and neutron capture therapy to specifically target and kill cancer cells.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: September 20, 2011
    Assignee: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino
  • Patent number: 7893286
    Abstract: Disclosed are improved methods for the synthesis of phospholipid ether analogs and alkyl phosphocholine analogs. The methods allow greater versatility of the reactants used and greater ease in synthesizing alkyl chains of varying length while affording reaction temperatures at room temperature or below. The methods disclosed herein provide reactants and conditions using alkyl halides and organozinc reagents and do not utilize Gringard reactions thus, allowing greater ease of their separation and purity of products. The PLE compounds synthesized by the methods disclosed herein can also be used for synthesizing high specific activity phospholipid ether (PLE) analogs, for use in treatment and diagnosis of cancer.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: February 22, 2011
    Assignee: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino
  • Patent number: 7811548
    Abstract: The invention generally relates to novel fluorescent phospholipid compounds and compositions comprising these compounds.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: October 12, 2010
    Assignee: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino, Irawati Kandela, William R. Clarke
  • Patent number: 7632644
    Abstract: The present invention generally relates to imaging and selective retention of phospholipid ether analogs in various neoplastic tissues. Specifically, the present invention relates to imaging and methods for selective retention of analogs, for example, NM404, in cancers such as Colorectal Cancer.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: December 15, 2009
    Assignee: Cellectar, Inc.
    Inventors: Jamey P. Weichert, Marc Longino, Sharon Weber, Joseph O. Nwankwo